Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Anticancer Drugs. 2014 Jan;25(1):123-5. doi: 10.1097/CAD.0000000000000024.
Our previous study showed that the features of epidermal growth factor receptor (EGFR)-RAS signaling in penile squamous cell carcinoma (SCC) suggested potential benefits of anti-EGFR monoclonal antibodies (mAbs) for penile SCC. Here, we report, for the first time, a combination of nimotuzumab (an EGFR mAb) with chemotherapy that resulted in a partial response in a 44-year-old patient with penile SCC, who developed bilateral inguinal node metastasis after primary partial penile amputation. The literature of case reports of anti-EGFR mAbs in penile SCC was also reviewed.
我们之前的研究表明，阴茎鳞癌（SCC）中表皮生长因子受体（EGFR）-RAS 信号的特征表明抗 EGFR 单克隆抗体（mAb）对阴茎 SCC 可能有益。在这里，我们首次报告了尼妥珠单抗（一种 EGFR mAb）联合化疗在一名 44 岁的阴茎 SCC 患者中的应用，该患者在原发性部分阴茎截肢后出现双侧腹股沟淋巴结转移。还回顾了抗 EGFR mAb 治疗阴茎 SCC 的病例报告文献。
